Journal
TRENDS IN CANCER
Volume 6, Issue 6, Pages 489-505Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2020.02.020
Keywords
-
Categories
Funding
- Precision Oncology Ireland - Science Foundation Ireland Strategic Partnership Programme [18/SPP/3522]
- SFI Starting Investigator Grant [15/SIRG/3528]
- EU H2020 MSCA [RISE-734749]
- Canada Research Chairs program
- Science Foundation Ireland (SFI) [15/SIRG/3528] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
Chemoresistance is a major factor driving tumour relapse and the high rates of cancer-related deaths. Understanding how cancer cells overcome chemotherapy-induced cell death is critical in promoting patient survival. One emerging mechanism of chemoresistance is the tumour cell secretome (TCS), an array of protumorigenic factors released by tumour cells. Chemotherapy exposure can also alter the composition of the TCS, known as therapy-induced TCS, and can promote tumour relapse and the formation of an immunosuppressive tumour microenvironment (TME). Here, we outline how the TCS can protect cancer cells from chemotherapy-induced cell death. We also highlight recent evidence describing how therapy-induced TCS can impact cancer stem cell (CSC) expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available